Drug Trial Radar · NCT03761225
Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Sep 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
714
Actual
Start
Sep 2014
Primary completion
Dec 15, 2020
Study completion Dec 15, 2020
Sponsor
- Lead sponsor
- AB ScienceIndustry
- Sponsor type
- Industry
- First posted
- Dec 3, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study of masitinib plus docetaxel as first-line chemotherapy in men with metastatic castration-resistant prostate cancer.
Conditions
- Metastatic Castrate Resistant Prostate Cancer
Interventions
MasitinibDrug
DocetaxelDrug
PrednisoneDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free SurvivalTime frame: From day of randomization to disease progression or death, assessed for a maximum of 60 months
Locations
9 sites in 6 countries. Site status is shown where the registry gives one.
Centre Hospitalier Universitaire de Sherbrooke
Sherbrooke, Canada
Polyclinique d'oncologie de Gentilly
Nancy, France
Sanjay Gandhi Post Graduate Institute of Medical Sciences
Lucknow, India
Centro di Riferimento Oncologico
Aviano, Italy
Istituto Europeo di Oncologia
Milan, Italy
Azienda Ospedaliero Universitaria Pisana
Pisa, Italy
Universiti Malaya Medical Centre
Kuala Lumpur, Malaysia
Clinical Oncology Dispensary
Omsk, Russia
Clinic Andros LLC
Saint Petersburg, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.